RevOptimal + OpenX Partnership Drives 0.13% CTR for HCP Campaign

MARKET EMULATION MODELS IN ACTION – ADJUSTING LAUNCH STRATEGY Our client had longitudinal patient data that had been acquired for the purpose of completing market definition, dynamics, and structure. We used the existing and updated patient data to build an MEM in the lead up to the launch of a new rare disease product. The MEM was used to refine launch planning, including targeting and forecasting. Post-launch, the use of the MEM transitioned into launch tracking, with different versions of the MEM created using different assumptions of likely HCP behaviour. The MEM proved to be a powerful tool and was an effective method of adjusting the post-launch activities, including implementing a patient communication programme that was not previously expected. Please visit https://tudorhealth.com/ or email info@tudorhealth.com to learn more about how a Tudor Health MEM could help with your future product launches. #druglaunch #healthcare #datascience

MARKET EMULATION MODELS IN ACTION – ADJUSTING LAUNCH STRATEGY Our client had longitudinal patient data that had been acquired for the purpose of completing market definition, dynamics, and structure. We used the existing and updated patient data to build an MEM in the lead up to the launch of a new rare disease product. The MEM was used to refine launch planning, including targeting and forecasting. Post-launch, the use of the MEM transitioned into launch tracking, with different versions of the MEM created using different assumptions of likely HCP behaviour. The MEM proved to be a powerful tool and was an effective method of adjusting the post-launch activities, including implementing a patient communication programme that was not previously expected. Please visit https://tudorhealth.com/ or email info@tudorhealth.com to learn more about how a Tudor Health MEM could help with your future product launches. #druglaunch #healthcare #datascience

$285,798 wasted. In a single month. 💸 If you’re relying on broad catalogue audiences to target prescribers, this is likely your reality. That’s the estimated monthly cost difference between targeting every HCP who prescribed in the last 24 months and refining to Soon-to-Prescribe HCPs showing active therapy signals. The industry norm is simple: target every historical prescriber. But historical prescribing behavior ≠ active patient need. 🎯 Broad catalogues tell you who prescribed in the past. They do not tell you who is actively managing therapy-relevant patient cases today. When spend is aligned to diagnosis-based signals instead, efficiency improves dramatically. In our latest blog, we break down: • Why static catalogues lose relevance the moment they’re published • How EHR and claims data identify Soon-to-Prescribe HCPs • How audience refinement reduces avoidable monthly spend Stop paying for past behavior. Start aligning spend with active patient demand. Read the full blog at the link in the comments. 🔗

The difference between “the market” and “in-market” is the difference between waste and efficiency. Manar Abbas wrote about the major waste we've seen in pharma marketing at Wrango. Some great insights to take away from the piece.

Historical prescribing ≠ current demand. One thing I’ve learned working in healthcare marketing is that audience strategy determines performance before a campaign even launches. Most pharma campaigns still target every HCP who prescribed in the last two years. But prescribing is event-driven. It happens because a physician is actively managing a patient case right now. That difference matters. When spend is built on broad historical lists, you’re paying for reach. When spend is aligned to diagnosis-based signals, you’re paying for relevance. And relevance is what drives efficiency. We broke this down in our latest Wrango blog: https://lnkd.in/eaNaAJzW

Digital patient recruitment is often treated as a downstream problem. In reality, many enrollment challenges originate much earlier - at the point where patient acquisition, targeting logic, and pre-screening structure are defined. At MediOra Health, we focus on upstream patient acquisition for clinical trials - building indication-based and study-specific digital funnels that deliver structured, pre-screened patient inflow into existing recruitment and trial-matching workflows. Especially in complex or competitive indications, the quality of the initial funnel determines the efficiency of everything that follows. Patient recruitment is not only about volume. It is about structure, logic, and data quality from the very first touchpoint.

Launching a new drug is a big step. But the..... real challenge starts after approval. The right doctors need to know about it, understand it, and see where it helps their patients. Today, awareness is not about reaching more people. Doctors already get too much information. What matters is sharing the right message with the right audience at the right time. 𝗪𝗵𝗮𝘁 𝘄𝗼𝗿𝗸𝘀 𝗯𝗲𝘁𝘁𝗲𝗿 𝗻𝗼𝘄: • Focus on the right specialists instead of broad outreach • Identify doctors who are actively looking into the disease area • Share simple, useful clinical information • Connect digital engagement with sales follow-up • Use data to focus time and effort where it matters most When outreach is focused and relevant, conversations become easier and adoption happens more naturally. At Ampliz, we support life sciences teams with healthcare data, intent signals, and targeted engagement so their outreach reaches the right HCPs without adding more noise. The goal is simple. Less noise. Better conversations. How are you approaching HCP awareness today? #PharmaMarketing #LifeSciences #DrugLaunch #HealthcareMarketing #HCPEngagement

More than a decade after the term Digital Opinion Leader was introduced, understanding digital influence is now central to how organisations identify and engage HCPs. In this article, Daniel Ghinn explores how Veeva Link Key People, IQVIA Expert Ecosystem and DOL Finder 2.0 approach #digitalinfluence, and how each platform surfaces #hcp activity across publications, conferences, clinical practice and online conversations. The piece looks at how organisations can move beyond simply knowing which KOLs are present on social media, towards understanding how HCPs “shape peer behaviour at scale” through real #digitalbehaviour and measurable #peerimpact. A practical comparison for teams working across #medicalaffairs, #healthcarecommunications and #pharmamarketing who want clearer visibility of influence in today’s therapeutic conversations. Read the full article: https://lnkd.in/eBBeqcdj

Clinical research isn’t just about proving efficacy, it’s a growth driver. In this clip, Kasia Feng (Green Chef), shares how investing in a clinical study didn’t just generate data, it helped double website traffic and significantly strengthen consumer trust. Not because of flashy product claims. Not because of marketing spin. But because real, transparent clinical evidence signals credibility in a crowded wellness market. When brands back their products with rigorous research, consumers engage more, stay longer, and convert with confidence. 👉 Missed the live session or want to revisit the insights? Watch the webinar on demand and explore how biomarkers can strengthen your next clinical study. https://lnkd.in/g9-mxyM5 #Citruslabs #ClinicalTrials #ClinicalResearch #Biomarkers